Antiglucocorticoid treatments for mood disorders

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Gallagher, Peter ^a   Malik, Navdeep ^b   Newham, James ^b   Young, Allan H ^c   Ferrier, I Nicol ^d   Mackin, Paul ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL; RETRACTED ARTICLE; REVIEW; ANTAGONISTS AND INHIBITORS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; HUMAN; META ANALYSIS; MOOD DISORDERS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

GLUCOCORTICOID; HYDROCORTISONE;

BIPOLAR DISORDER; DEPRESSIVE DISORDER; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MOOD DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84957791408     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD005168.pub3     Document Type: Review

References (77)

1. BelanoffJK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. Journal of Clinical Psychopharmacology 2001;21(5):516-21.
2. DeBattista C, BelanoffJ. A double-blind, placebo controlled trial of C-1073 (Mifepristone) in the treatment of psychotic major depression. Neuropsychopharmacology 2004;29 Suppl 1:S98.
3. DeBattista C, BelanoffJ, Glass S, Khan A, Horne RL, Blasey C, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biological Psychiatry 2006;60(12):1343-9.
4. Jahn H, Schick M, Kiefer F, Arlt J, Kampf P, Wiedemann K. Preliminary results of a prospective, double-blind, placebo controlled study of metyrapone as an adjunct in the treatment of major depression. European Neuropsychopharmacology 2002;12 Suppl 3:S197.
5. Jahn H, Schick M, Kiefer F, Kellner M, Yassouridis A, Wiedemann K. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial. Archives of General Psychiatry 2004;61(12):1235-44.
6. Malison RT, Anand A, Pelton GH, Kirwin P, Carpenter L, McDougle CJ, et al. Limited efficacy of ketoconazole in treatment-refractory major depression. Journal of Clinical Psychopharmacology 1999;19:466-70.
7. O'Dwyer AM, Lightman SL, Marks MN, Checkley SA. Treatment of major depression with metyrapone and hydrocortisone. Journal of Affective Disorders 1995;33(2):123-8.
8. Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006;31:628-36.
9. Schatzberg AF. HPA Axis/Dopamine interactions in psychotic depression. www.clinicaltrials.gov 2004.
10. Schatzberg AF, Flores B, Solvason HB, Keller J, Gumina HK. Mifepristone in psychotic major depression. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, NY. 2004:NR397.
11. Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, et al. Antiglucocorticoid treatment of depression: double-blind ketoconazole. Biological Psychiatry 1999;45(8):1070-4.
12. Wolkowitz OM, Reus VI, Vinogradov S, Chan T, Manfredi F, Marco E, et al. Antiglucocorticoids in depression and schizophrenia. 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, NY. 1996.
13. Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E, et al. Dehydroepiandrosterone treatment of major depression. 152nd Annual Meeting of the American Psychiatric Association, 1999 May 15-20, Washington, DC. 1999.
14. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al. Double-blind treatment of major depression with dehydroepiandrosterone. American Journal of Psychiatry 1999;156(4):646-9.
15. Young AH. The HPA axis in affective disorders: A suitable case for treatment?. Australian and New Zealand Journal of Psychiatry 2005;39 Suppl 2:A24-A25.
16. Young AH, Gallagher P, Watson S, Del-Estal D, Owen BM, Ferrier IN. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004;29(8):1538-45.
17. Anand A, Malison R, McDougle CJ, Price LH. Antiglucocorticoid treatment of refractory depression with ketoconazole: a case report. Biological Psychiatry 1995;37(5):338-40.
18. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine 1999;341(14):1013-20.
19. BelanoffJK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry 2002;52:386-92.
20. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biological Psychiatry 1999;45:1533-41.
21. Brown ES, Bobadilla L, Rush AJ. Ketoconazole in bipolar patients with depressive symptoms: a case series and literature review. Bipolar Disorders 2001;3(1):23-9.
22. Cruess DG, Antoni MH, Kumar M, Ironson G, McCabe P, Fernandez JB, et al. Cognitive-behavioral stress management buffers decreases in dehydroepiandrosterone sulfate (DHEA-S) and increases in the cortisol/DHEA-S ratio and reduces mood disturbance and perceived stress among HIV-seropositive men. Psychoneuroendocrinology 1999;24(5):537-49.
23. Fabian TJ, Dew MA, Pollock BG, Reynolds CF, Mulsant BH, Butters MA, et al. Endogenous concentrations of DHEA and DHEA-S Decrease with remission of depression in older adults. Biological Psychiatry 2001;50(10):767-74.
24. Fava M, Rosenbaum JF, MacLaughlin RA, Tesar GE, Pollack MH, Cohen LS, et al. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Research 1989;28(3):345-50.
25. Freeman EW, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Womens Health and Gender Based Medicine 2001;10(6):561-9.
26. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, et al. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biological Psychiatry 1995;37:369-75.
27. Gordon CM, Grace E, Emans SJ, Feldman HA, Goodman E, Becker KA, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. Journal of Clinical Endocrinology and Metabolism 2002;87(11):4935-41.
28. Kalman DS, Colker CM, Swain MA, Torina GC, Shi Q. A randomized, double-blind, placebo-controlled study of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy overweight adults. Current Therapeutic Research, Clinical and Experimental 2000;61(7):435-42.
29. Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, et al. Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder. Biological Psychiatry 2001;50:238-45.
30. Kling MA, Whitfield HJ, Brandt HA, Demitrack MA, Kalogeras K, Geracioti TD, et al. Effects of glucocorticoid antagonism with RU 486 on pituitary-adrenal function in patients with major depression: time-dependent enhancement of plasma ACTH secretion. Psychopharmacology Bulletin 1989;25(3):466-72.
31. Kling MA, Demitrack MA, Whitfield HJ, Kalogeras KT, Listwak SJ, DeBellis MD, et al. Effects of the glucocorticoid antagonist RU 486 on pituitary-adrenal function in patients with anorexia nervosa and healthy volunteers: enhancement of plasma ACTH and cortisol secretion in underweight patients. Neuroendocrinology 1993;57(6):1082-91.
32. Lightman S. Placebo controlled investigations of the effects of metyrapone treatment upon mood and neuroendocrine function in patients with major depression. National Research Register 1997.
33. Murphy BE, Filipini D, Ghadirian AM. Possible uses of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU-486. Journal of Psychiatry and Neuroscience 1993;18(5):209-13.
34. Murphy BE, Dhar V, Ghadirian AM, Chouinard G, Keller R. Response to steroid suppression in major depression resistant to antidepressant therapy. Journal of Clinical Psychopharmacology 1991;11(2):121-6.
35. Papolos DF, Edwards E, Marmur R, Lachman HM, Henn FA. Effects of the antiglucocorticoid RU 38486 on the induction of learned helpless behavior in Sprague-Dawley rats. Brain Research 1993;615(2):304-9.
36. Rabkin JG, Ferrando SJ, Wagner GJ, Rabkin R. DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters. Psychoneuroendocrinology 2000;25(1):53-68.
37. Reiter WJ, Pycha A. Placebo-controlled dihydroepiandrosterone substitution in elderly men. Gynakologisch-Geburtshilfliche Rundschau 1999;39(4):208-9.
38. Stowell CP, Nollie, DL, Baptiste MJ, Bowers MB. Effectiveness of antiglucocortcoid therapy in a patient with psychotic depression and ectopic ACTH production. Journal of Psychiatric Practice 2003;9(4):321-3.
39. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Archives of General Psychiatry 2003;60:133-41.
40. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstetricia et Gynecologica Scandinavica 1995;74(10):803-8.
41. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biological Psychiatry 1997;41(3):311-8.
42. Young AH, Gallagher P, Porter RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. American Journal of Psychiatry 2002;159(7):1237-9.
43. Daly RJ, Schmidt PJ, Bloch M. DHEA in midlife onset depression. 2nd World Congress on Women's Mental Health. Washington, DC.; March 18. 2004.
44. DenicoffKD, Singh J, Sporn J, Zarate CA, Quiroz JA, Brutsche NE, et al. Antiglucocorticoid therapy in bipolar depression with mifepristone. Bipolar Disorders 2005;7 Suppl 2:47.
45. Korszun A, Broadley AJ, Moskvina V, Jones CI, Frenneaux MP. Metyrapone reverses impaired endothelial function in depressed patients. 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco CA. 2003.
46. Reus VI, Wolkowitz OM. Dehydroepiandrosterone treatment of Alzheimer's Disease and major depression. 156th Annual Meeting of the American Psychiatric Association, May 17-22, San Francisco CA. 2003.
47. Ongoing study Starting date of trial not provided. Contact author for more information.
48. Kocsis JH. Safety study of ORG 34517 for major depression with psychotic features. www.controlled-trials.com 2006.
49. Ongoing study Starting date of trial not provided. Contact author for more information.
50. Solvason BH. Mifepristone in refractory depression. www.controlled-trials.com 2006.
51. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
52. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th Edition. Washington DC: American Psychiatric Association, 1994.
53. Clark L, Sarna A, Goodwin GM. Impairment of executive function but not memory in first-degree relatives of patients with bipolar I disorder and in euthymic patients with unipolar depression. American Journal of Psychiatry 2005;162:1980-2.
54. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatric Clinics of North America 2005;28:469-80.
55. DeBattista C, BelanoffJ. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends in Endocrinology & Metabolism 2006;17:117-21.
56. Ferrier IN, Thompson JM. Cognitive impairment in bipolar affective disorder: implications for the bipolar diathesis. British Journal of Psychiatry 1999;180:293-5.
57. Forget H, Lacroix A, Somma M, Cohen H. Cognitive decline in patients with Cushing's syndrome. Journal of the International Neuropsychological Society 2000;6:20-9.
58. Gallagher P, Young AH. Mifepristone (RU-486) treatment of depression and psychosis: a review of the therapeutic implications. Neuropsychiatric Disease and Treatment 2006;2:33-42.
59. Gibbons JL. Cortisol secretion rate in depressive illness. Archives of General Psychiatry 1964;10:572-5.
60. Heuser I, Yassouridis A, Holsboer F. The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. Journal of Psychiatric Research 1994;28:341-56.
61. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002;21(11):1539-58.
62. Lupien SJ, McEwen BS. The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Research. Brain Research Reviews 1997;24:1-27.
63. Marcos T, Salamero M, Gutierrez F, Catalan R, Gasto C, Lazaro L. Cognitive dysfunctions in recovered melancholic patients. Journal of Affective Disorders 1994;32:133-7.
64. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. American Journal of Psychiatry 2004;161:262-70.
65. McQuade R, Young AH. Future therapeutic targets in mood disorders: the glucocorticoid receptor. British Journal of Psychiatry 2000;177:390-5.
66. Murphy BE, Filipini D, Ghadirian AM. Possible uses of glucocorticoid receptor antagonists in the treatment of major depression: Preliminary results using RU-486. Journal of Psychiatry and Neuroscience 1993;18:209-13.
67. Murphy BE. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology 1997;22:S125-32.
68. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349(9063):1436-42.
69. Parker LN. Adrenal Androgens in Clinical Medicine. San Diego, CA: Academic Press, 1989.
70. Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. British Journal of Psychiatry 2003;182:214-20.
71. Porter RJ, Gallagher P. Abnormalities of the HPA axis in affective disorders: clinical subtypes and potential treatments. Acta Neuropsychiatrica 2006;18:193-209.
72. Reus VI, Wolkowitz OM. Antiglucocorticoid drugs in the treatment of depression. Expert Opinion on Investigational Drugs 2001;10(10):1789-96.
73. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, et al. A meta-analysis of cognitive deficits in euthymic bipolar subjects. Journal of Affective Disorders 2006;93:105-15.
74. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker CR Jr, Weissenburger JE, et al. The dexamethasone suppression test in patients with mood disorders. Journal of Clinical Psychiatry 1996;57(10):470-84.
75. Sackett D. Cochrane Collaboration Handbook. Oxford: Update Software, 1997.
76. Thakore JH, Dinan TG. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biological Psychiatry 1995;37:364-8.
77. World Health Organisation. The tenth revision of the International Classification of Diseases and related health problems (ICD-10). Geneva: World Health Organisation, 1992.